Citation: | SHI Qinqing, WANG Jinghua, CHENG Manman, YIN Lifang, QIN Chao. Preparation and in vitro release of ivabradine hydrochloride elementary osmotic pump tablets[J]. Journal of China Pharmaceutical University, 2021, 52(3): 311-317. DOI: 10.11665/j.issn.1000-5048.20210307 |
[1] |
. Pharmacol Res,2006,53(5):424-434.
|
[2] |
Li JD,Gan T. The clinical application of If current inhibitor ivabradine[J]. J Clin Cardiol(临床心血管病杂志),2020,36(3):212-214.
|
[3] |
Electronic Medicines CompendiumUK.Summary of product characteristics of procoralan[EB/OL].(
|
[4] |
Mullasari A,investigatorsPROFICIENT. Efficacy and safety of ivabradine once-daily prolonged-release versus twice-daily immediate-release formulation in patients with stable chronic heart failure with systolic dysfunction:a randomized,double-blind,phase 3 non-inferiority (PROFICIENT) study[J]. Cardiol Ther,2020,9(2):505-521.
|
[5] |
Xu X,Wei YL,Ji W,et al. Pharmacokinetic profile of ivabradine hemisulfate sustained-release tablets administered in Chinese healthy volunteers:an open-label,randomized,single-dose,three-period crossover study[J]. Biomed Chromatogr,2019,33(11):
|
[6] |
Ma L. Progress in osmotic pump drug delivery system[J]. J China Pharm Univ(中国药科大学学报),2014,45(6):726-730.
|
[7] |
Thombre AG,Appel LE,Chidlaw MB,et al. Osmotic drug delivery using swellable-core technology[J]. J Control Release,2004,94(1):75-89.
|
[8] |
Malaterre V,Ogorka J,Loggia N,et al. Oral osmotically driven systems:30 years of development and clinical use[J]. Eur J Pharm Biopharm,2009,73(3):311-323.
|
[9] |
Zhu L,Qin C,Wu JL,et al. Preparation and in vitro evaluation of pregabalin controlled porosity osmotic pump tablets[J]. J China Pharm Univ(中国药科大学学报),2019,50(1):53-58.
|
[10] |
Masciocchi N,Aulisio A,Bertolini G,et al. Disclosing the extensive crystal chemistry of Ivabradine hydrochloride,in its pure and solvated phases[J]. Powder Diffr,2013,28(3):200-206.
|
[11] |
Zhou XB,Zhu JR,Liu JY,et al. Crystal structures and properties of two hydrated conglomerate forms of the heart-rate-lowering agent ivabradine hydrochloride[J]. Acta Crystallogr C Struct Chem,2019,75(
|
[12] |
Waterman KC,MacDonald BC,Roy MC. Extrudable core system:development of a single-layer osmotic controlled-release tablet[J]. J Control Release,2009,134(3):201-206.
|
[13] |
Smith AP,Moore TW,Westenberger BJ,et al. In vitro dissolution of oral modified-release tablets and capsules in ethanolic media[J]. Int J Pharm,2010,398(1/2):93-96.
|
[14] |
Jedinger N,Khinast J,Roblegg E. The design of controlled-release formulations resistant to alcohol-induced dose dumping:a review[J]. Eur J Pharm Biopharm,2014,87(2):217-226.
|
[15] |
Costa P,Sousa Lobo JM. Modeling and comparison of dissolution profiles[J]. Eur J Pharm Sci,2001,13(2):123-133.
|